What is driving DMAA stock right now?

The SPAC’s definitive merger agreement sets a $2.85 B valuation and outlines a domestication and merger structure, likely driving significant price movement. The 8-K is a material deal-structure update that can change dilution, economics, and closing conditions for DMAA’s SPAC-to-PAGC combination. The successful IPO indicates strong investor interest, potentially leading to increased trading activity and positive sentiment towards the company's future prospects.

DMAA — Drugs Made In America Acquisition news & insider trades

Price · $DMAAvia TradingView

AI sentiment · 7d1 articles

SEP 11net (bullish − bearish)SEP 17

Bullish: 1
Neutral: 0
Bearish: 0

Insider · 30dAll trades →

No SEC Form 4 filings for $DMAA in the last 30 days.

See all $DMAA insider activity →

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

Drugs Made In America Acquisition Corp. (DMAA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Background As previously disclosed, on April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Original Agreement”

JUL 20·SEC EDGAR 8-K

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

Drugs Made In America Acquisition Corp. (DMAA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0002028614 0002028614 2026-07-14 2026-07-14 0002028614 DMAA:UnitsEachConsistingOfOneOrdinaryShareParValue0.0001PerShareAndOneRightToReceiveOneeighth18OfOrdinaryShareMember 2026-07-14 2026-07-14 0002028614 DMAA:OrdinarySharesMember 2026-07-14 2026-07-14 0002028614 us-gaap:Ri

SEP 26·GlobeNewswire

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

Fort Lauderdale, FL, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Drugs Made In America Acquisition II Corp. ( Nasdaq: DMIIU ) ( the "Company" ) today announced that it closed its initial public offering of 50,000,000 units at $10.00 per unit. The gross proceeds from the offering were $500 million before ...

via TradingView

DMAA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning DMAA (Drugs Made In America Acquisition Corp.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent DMAA coverage spans financial news and corporate actions.

What's driving DMAA

The SPAC’s definitive merger agreement sets a $2.85 B valuation and outlines a domestication and merger structure, likely driving significant price movement.
SEC EDGAR 8-K · Sep 14, 2026
The 8-K is a material deal-structure update that can change dilution, economics, and closing conditions for DMAA’s SPAC-to-PAGC combination.
SEC EDGAR 8-K · Jul 20, 2026
The successful IPO indicates strong investor interest, potentially leading to increased trading activity and positive sentiment towards the company's future prospects.
GlobeNewswire · Sep 26, 2025
The IPO announcement of Drugs Made In America Acquisition II Corp. (DMAA) has limited immediate impact on the stock's price or broader market sectors.
GlobeNewswire · Sep 25, 2025
Limited direct influence on DMAA; the news primarily affects pharmaceutical and biotech sectors.
GlobeNewswire · Sep 16, 2025

AlphAI scores every news story that mentions DMAA with an AI model for sentiment and relevance, and aggregates insider trades from Drugs Made In America Acquisition Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DMAA

Score

SEP 14$DMAAHighSEC EDGAR 8-K

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

2 min read

JUL 20$DMAAMedSEC EDGAR 8-K

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

4 min read

SEP 26$DMAAMedGlobeNewswire

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

2 min read

SEP 25$DMAALowGlobeNewswire

Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Fort Lauderdale, FL, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- Drugs Made In America Acquisition II Corp. ( Nasdaq: DMIIU ) ( the "Company" ) announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit.

2 min read

SEP 16$DMAAMedGlobeNewswire

PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A

Fort Lauderdale, FL, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market ( TAM ) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers.

4 min read

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

DMAA sentiment & insider activity

What's driving DMAA

News on $DMAA

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A

Related tickers